Protagonist Therapeutics, Inc. - Common Stock (PTGX)
87.00
+19.96 (29.77%)
NASDAQ · Last Trade: Oct 10th, 8:15 PM EDT
Detailed Quote
Previous Close
67.04
Open
67.39
Bid
87.38
Ask
89.00
Day's Range
65.75 - 93.25
52 Week Range
33.31 - 93.25
Volume
7,065,392
Market Cap
5.40B
PE Ratio (TTM)
119.18
EPS (TTM)
0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,280,349
Chart
About Protagonist Therapeutics, Inc. - Common Stock (PTGX)
Protagonist Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapeutic solutions for patients suffering from a range of serious diseases. The company employs a unique approach that combines peptide-based drug discovery with advanced technologies to create targeted therapies, aiming to address unmet medical needs in areas such as gastrointestinal conditions, inflammatory diseases, and oncology. With a commitment to scientific rigor and collaboration, Protagonist is advancing its pipeline of drug candidates through clinical trials, striving to bring new treatments to market that can significantly improve patient outcomes. Read More
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC study
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies
NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral presentation at the United European Gastroenterology Week 2025 being held in Berlin, Germany from October 4th through June 7th, 2025.
NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences taking place in September.
Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development program
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session (LBA3) at 2:09 pm CDT today.
